Abstract: New anisotropic compounds with a cross-polarizing substituent have the formula (1) ##STR1## The increase in .epsilon..perp. is achieved by the polarizing group X, preferably the cyano group or a halogen atom, which is not laterally on the ring, as with the known compounds, but is on the bridge, that is to say is part of the main bridge bonding rings A and B to one another. Ring A has the formula (1a) or (1b) given herein and is always cycloaliphatic, while ring B can be identical to ring A or is an aromatic ring of the formula (1c) or (1d) herein. R.sup.1 and R.sup.2 are identical or different end groups of the formula (1e) herein. The radical X on the bridge causes less widening of the molecule than a radical X on a ring, which provides comparatively higher clear points and moreover enables aromatic rings to be omitted from the anisotropic compounds.

Abstract: Liquid crystalline mixtures containing compounds of the formula ##STR1## wherein n stands for the number 0 or 1; X.sup.1 and X.sup.2 denote single covalent bonds or one of the symbols X.sup.1 and X.sup.2 also denotes --COO--, --OOC-- or --CH.sub.2 CH.sub.2 --; the rings A.sup.1, A.sup.2, and A.sup.3 represent 1,4-phenylene, 2-fluoro-1,4-phenylene or trans-1,4-cyclohexylene or one of these rings also represents a 2,5-disubstituted pyrimidine ring or a trans-2,5-disubstituted m-dioxane ring; R.sup.1 signifies 4-alkenyl or on a cyclohexyl ring also 2Z-alkenyl; and R.sup.2 denotes alkyl, alkoxy, --CN or --NCS,as well as the manufacture of these compounds and the use for electro-optical purposes are described.

Abstract: New hydroterphenyls of formula IR.sup.1 --Cy--Cy--Ph--R.sup.2 Iwherein R.sup.1 is alkyl; R.sup.2 is H, F, Cl, Br, I, OH, CN, alkyl, --O-alkyl, --COOR.sup.3 or --O--CO--R.sup.3 ; R.sup.3 is H, alkyl, --Cy-alkyl, --Ph-alkyl, --Ph--O-alkyl, --Ph--CN or --Ph--F; Cy is 1,4-cyclohexylene; and Ph is 1,4-phenylene; can be used as dielectrics for electrooptical display elements.

Abstract: Bicyclohexyl derivatives of formula IR.sup.1 --Cy--Cy--X--Y IwhereinX is --CO--O-- or --O--CO--,Y is alkyl or perfluoroalkyl in each case of 1-8 C atoms, --Cy--Cy--R.sup.2, --Cy--Ph--R.sup.2, --Ph--Cy--R.sup.2, --Ph--Ph--R.sup.2 or --Ph--Dio--R.sup.2,Cy is 1,4-cyclohexylene,Ph is 1,4-phenylene,Dio is 1,3-dioxane-2,5-diyl andR.sup.1 and R.sup.2 are each alkyl or alkoxy in each case of 1-8 C atoms,can be used as components of liquid crystal dielectrics.

Abstract: Esterification of aromatic dicarboxylic acids with cyclic alkylene carbonates in the presence of organic compounds containing at least one six-membered aromatic nitrogen-containing heterocyclic moiety.

Abstract: Novel ferroelectric liquid crystalline compounds having a superior stability and chiral, smectic liquid crystalline compositions containing at least one kind of the same are provided, which compounds are expressed by the general formula ##STR1## wherein ##STR2## represents 1,4-phenylene group ##STR3## or 1,4-trans-cyclohexane group ##STR4## R*, an optically active alkyl group; m=o, 1 or 2; n=1 or 2; X, a linear chain or branched alkyl group or alkoxy group, each having 1 to 18 carbon atoms; and when ##STR5## represents ##STR6## m=1; and n=1, X represents a linear chain or branched alkyl group having 1 to 18 carbon atoms or a linear chain alkoxy group having 11 to 18 carbon atoms.

Abstract: Psoriasis in mammals is relieved by topically administering naphthalenes of the formula: ##STR1## wherein: R.sup.1 and R.sup.2 are the same and are lower alkoxy, lower alkylthio, optionally substituted phenoxy or optionally substituted phenylthio,R.sup.3 is lower alkyl, lower alkoxy, or halo and m is 0, 1 or 2 or R.sup.3 is optionally substituted phenyl, optionally substituted phenyl lower alkyl, optionally substituted phenyl lower alkoxy, amino, lower alkylamino, lower dialkylamino, cyano, or S(O).sub.n R wherein R is lower alkyl; optionally substituted phenyl; optionally substituted phenyl lower alkyl; or optionally substituted heterocyclic aryl of three to nine ring atoms containing one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and the pharmaceutically acceptable acid addition salts thereof; and m is 1 and n is 0, 1 or 2; andW is alkyl of one to seven carbon atoms, optionally substituted phenyl or optionally substituted benzyl.

Abstract: The present invention is characterized by a smectic liquid crystal compound represented by the following formula: ##STR1## wherein R is selected from alkyl and alkoxy groups; X from ##STR2## m and n are natural numbers; and R* is an optically active group containing an asymmetric carbon atom, and a liquid crystal composition containing said compound as a component. This compound is excellent in optical stability and high-speed response.

Abstract: Amidino compounds represented by the formula ##STR1## and pharmaceutically acceptable acid addition salts thereof are novel compounds and are useful as powerful anti-trypsine, anti-plasmin, anti-kallikrein and anti-thrombin agents. Having strong anti-Cl (Clr, Cls) activities and an anticomplement activity, they are also useful as anticomplement agents. These amidino compounds are prepared by usual esterification of carboxylic acid compounds represented by the formula (II)R.sub.1 --COOH (II)with amidinophenol compound (III) and, if necessary, can be transformed into pharmaceutically acceptable acid addition salts thereof.

Abstract: A colorless liquid crystalline compound having at least one 6-membered ring and non-cyclic end groups in the molecular skelton, said 6-membered containing two or more carbon atoms, at least one of which is directly bonded to a methylene group of a non-cyclic group having an alkoxy group at another end has a wide mesomorphic range. When said colorless liquid crystalline compound is mixed with a liquid crystal composition, the resulting mixture also has an enlarge mesomorphic range and in almost all cases has a reduced viscosity.

Abstract: Ferroelectric (chiral) smectic liquid crystal compounds having an achiral core and chiral tail units derived from lactic acid possess the desired combination of properties temperature range, ferroelectric polarization, and low orientational viscosity. These newly made compounds exhibit high speed, multistate electro-optic switching properties which make them ideally suited to certain electro-optic and display device applications.

Abstract: The title compounds correspond to the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are alkyl, A is alkylene, X is --NH-- or --S--, m is 1 and n is 0 or 1, and are useful as stabilizers for organic polymers and lubricating oils to counteract the degradative effects of heat, light and air.

Abstract: New polyhalogenoaromatic compounds of Formula I ##STR1## wherein Y and Z are each independently alkyl, alkoxy or alkanoyl each of 1 to 12 C atoms, --COOR.sup.1, --O--CO--R.sup.1, CN, NO.sub.2, NH.sub.2 or OH;Q is one or two identical or different radicals selected from Ph, Cy, 1,4-bicyclo[2,2,2]octylene or 1,3-dioxane-2,5-diyl;X.sup.1 to X.sup.4 are each independently H, F, Cl or Br;R.sup.1 is alkyl of 1 to 4 C atoms, Ph--R.sup.2 or Cy--R.sup.2 ;R.sup.2 is alkyl or alkoxy each of 1-12 C atoms or CN;Ph is 1,4-phenylene; and Cy is 1,4-cyclohexylene,can be used as components of liquid-crystal dielectrics.

Abstract: Novel 3-hydroxy-4-alkyloxyphenyl benzoates compounds particularly well suited as sweeteners in foodstuff.

Abstract: Novel compounds of the metal salts of certain phenol ester sulfonic acids are useful as a flame retardant additive in polycarbonate composition.

Abstract: Compounds of the formula ##STR1## wherein ring B stands for 1,4-phenylene or a trans-1,4-disubstituted cyclohexane ring and A stands for a group with 1 to 3 six-membered rings, which together with ring B represents a central group of formulae II-XIII; R.sup.1 signifies a straight-chain alkyl group containing 1 to 9 carbon atoms or when R.sup.1 is attached to a benzene, monofluorinated benzene or pyrimidine, ring R.sup.1 also signifies a straight-chain alkoxy group with 1 to 9 carbon atoms; and R.sup.2 signifies hydrogen, cyano or a straight-chain alkyl group containing 1 to 7 carbon atoms,their manufacture, liquid crystalline mixtures which contain said compounds and their use for electro-optical purposes are described.The compounds of formula I are especially valuable as components in liquid crystal mixtures and for the most part themselves have liquid crystalline properties.

Abstract: Compounds of the formula ##STR1## wherein n is 0 or 1; one of X.sup.1 and X.sup.2 is --COO-- or --OOC-- and the other is a single covalent bond or --CH.sub.2 CH.sub.2 --; X.sup.3 and X.sup.4 individually are a single covalent bond or --CH.sub.2 CH.sub.2 --, with the proviso that at most one of X.sup.1, X.sup.2, X.sup.3 and X.sup.4 is --CH.sub.2 CH.sub.2 --; rings A.sup.1 and A.sup.5 individually are a group of the formula ##STR2## or trans-1,4-cyclohexylene; rings A.sup.2, A.sup.3 and A.sup.4 individually are a group of formula II or, when ring A.sup.2, A.sup.3 or A.sup.4 is not linked with at least one of the other two of these rings by a single covalent bond then such ring also can be trans-1,4-cyclohexylene, with the proviso that at least one of rings A.sup.1 through A.sup.5 is a group of formula II; Y is hydrogen, or when Y is attached to a ring of formula II which is not linked with another ring via a single covalent bond, Y also can be fluorine, chlorine or methyl; and R.sup.1 and R.sup.

Abstract: The invention relates to nematic liquid crystals in electro-optical components for the modulation of light as well as for the representation of numerals, signs and images and to a method for producing the same.It is the object of the invention to create nematic liquid crystals which are well suited for electro-optical devices, preferably for two-frequency operation.It has been found that pure or mixed 2-n-alkyl-1, 4-bis-[4-acyloxy]-benzenes of the general formula ##STR1## wherein R.sup.3 =n-C.sub.m H.sub.2m+1, with m=3 to 14, are well suited for utilization in electro-optical components.It was found that 2-n-alkyl-1,4-bis-[acyloxy]-benzene which is well suited for electro-optical components, and especially for two-frequency operations, can be produced by the conversion of a correspondingly substituted benzoic acid or cyclohexane carboxylic acid or a reaction-capable derivative thereof with the corresponding 2-n-alkylhydroquinone--also in the form of its phenylate--at a temperature ranging from 0.degree. C.

Abstract: Amidino compounds represented by the formula (I) ##STR1## and pharmaceutically acceptable acid addition salts thereof are novel compounds and are useful as powerful antitrypsine, antiplasmin, antikallikrein and anti-thrombin agents. Having strong anti-Cl (Clr, Cls) activities and an anticomplement activity, they are also useful as anticomplement agents. These amidino compounds are prepared by usual esterification of carboxylic acid compounds represented by the formula (II)R.sub.1 --COOH (II)with amidinophenol compound (III) and, if necessary, can be transformed into pharmaceutically acceptable acid addition salts thereof.

Abstract: Novel compounds of general formula I ##STR1## wherein R is a branched or unbranched alkyl, cycloalkyl, or aralkyl group, which group optionally contains or is substituted by a halogen or oxygen function, the oxygen function optionally being in the form of an alcohol or ether moiety;R.sub.1, R.sub.2, and R.sub.3, which may be the same or different, is hydrogen, an alkyl, acyl, or benzoyl group, which group optionally contains or is substituted by a halogen or oxygen function;R.sub.4 is hydrogen, an alkyl, alkenyl preferably being an allyl or prenyl group, or aralkyl group which group optionally contains or is substituted by an alkyl, aryl, halogen or oxygen function;R.sub.5 is hydrogen, an alkyl, aralkyl, acyl, or aryl group, which group optionally contains or is substituted by an alkyl, aryl, halogen, or oxygen function;except that R.sub.4 and R.sub.5 are not both hydrogen;and except for the compounds when R.sub.

Abstract: Amidino compounds represented by the formula (I) ##STR1## and pharmaceutically acceptable acid addition salts thereof are novel compounds and are useful as powerful antitrypsine, antiplasmin, antikallikrein and anti-thrombin agents. Having strong anti-Cl (Clr, Cls) activities and an anticomplement activity, they are also useful as anticomplement agents. These amidino compounds are prepared by usual esterification of carboxylic acid compounds represented by the formula (II)R.sub.1 --COOH (II)with 4-(.beta.-amidinoethenyl)phenol represented by the formula (III) ##STR2## and, if necessary, can be transformed into pharmaceutically acceptable acid addition salts thereof.

Abstract: Fluorine-containing phenyl benzoate compounds which have the general formula: ##STR1## wherein R is a C.sub.1 -C.sub.12 perfluoroalkyl group, a C.sub.1 -C.sub.12 alkyl group, a C.sub.1 -C.sub.12 alkoxy group, a C.sub.2 -C.sub.13 alkanoyloxy group, a C.sub.2 -C.sub.13 alkoxycarbonyl group, a C.sub.2 -C.sub.13 alkoxycarbonyloxy group or a C.sub.2 -C.sub.13 alkyldioxycarbonyl group and X is a C.sub.1 -C.sub.12 alkyl group, a C.sub.1 -C.sub.12 alkoxy group, a cyano group, a trifluoromethyl group or a nitro group with the proviso that X is trifluoromethyl when R is other than perfluoroalkyl are useful as components of liquid crystals.

Abstract: Sulfonyl or carbonyl derivatives of inositols are found to be effective phospholipase C inhibitors and thereby potent anti-inflammatory and analgesic agents. These inositol derivatives are prepared by condensation of a protected inositol with a substituted sulfonic or carboxylic acid derivative followed by removal of protecting groups.

Abstract: 4-Fluorobiphenyl derivatives of the formula (I) ##STR1## wherein X is --CO--O-- or --O--CO--; Z is 1,4-phenylene or 1,4-cyclohexylene; and R is alkyl, alkoxy or alkanoyloxy, each of 1 to 8 atoms, are valuable components of liquid-crystalline dielectrics for electro-optical applications.

Abstract: A nematic liquid crytalline compound selected from the group consisting of compounds represented by the general formula ##STR1## compounds represented by the general formula ##STR2## compounds represented by the general formula ##STR3## and compounds represented by the general formula ##STR4## wherein R and R', independently from each other, represent a linear alkyl group having 1 to 7 carbon atoms, and each cyclohexane ring is arranged in a trans(equatorial-equatorial) form. These compounds have higher nematic phaseisotropic liquid phase transition temperatures than conventional liquid crystalline compounds.

Abstract: A process for making polyether/polyester glycols and the products formed thereby. Polyether/polyester glycols having a molecular weight of about 200 to 2,200 are formed by heating any of various glycols at about 150.degree. to 250.degree. C. under carbon monoxide pressure in the presence of a halide promoter. Preferably, iodide or bromide and a transition metal-containing catalyst are used to produce polyether/polyester glycols having a molecular weight in the range of 900 to 1,200.

Abstract: Disclosed is a process for the preparation of aryl 1-hydroxyaryl-2-carboxylates by the reaction of certain phenolic compounds with an aryl chloroformate in the presence of aluminum chloride and an organic solvent.

Abstract: New bronchospasmolytically active compounds exhibiting long duration of action and reduced undesired side effects, of the structural formula ##STR1## and therapeutically acceptable salts thereof, in which formula R, R.sup.1 and R.sup.2 are as follows:R is selected from the group consisting of --C(CH.sub.3).sub.3, ##STR2## R.sup.1 is selected from the group consisting of H and R.sup.2 ; R.sup.2 is selected from the group consisting of ##STR3## in which formulas R.sup.3 is selected from the group consisting of (a) H; ##STR4## wherein R.sup.5 is a straight or branched alkyl group containing 1-4 carbon atoms;and ##STR5## and wherein R.sup.4 is selected from the group consisting of(a) H(b) an alkyl group containing 1-3 carbon atoms,process for the preparation thereof, chemical intermediates at their preparation, pharmaceutical compositions containing them and their medicinal use.

Abstract: Milbemycin and avermectin macrolides are synthesized by the cyclized linking of separately synthesized northern and southern hemisphere intermediates. The northern hemisphere intermediate is a spiroketal alkenyl aldehyde, and the southern hemisphere intermediate is an aryl alkenyl phosphine oxide anion.

Abstract: Di and trihydroxybenzohydroxamic acids, amides, alkyl substituted amides and phenyl esters, ribonucleotide reductase inhibitors.

Abstract: The invention relates to methyl- or methoxy-substituted 2-cynnamoyloxy-benzoic acids or to cynnamylesters of methyl- or methoxy-substituted 2-hydroxybenzoic acids, endowed with an interesting antiinflammatory, analgesic and antibacterial activity; and to a process for preparing said compounds.

Abstract: Novel substituted benzoyloxy compounds exhibit plant regulator activity, retarding or stimulating the growth of a variety of broadleaved plants, while leaving grasses unaffected. The preparation and plant regulator activity of the compounds is exemplified.

Abstract: Novel phenolically substituted esterbisamides as antioxidants useful for the protection of organic materials such as synthetic and natural rubbers, plastics and petroleum products against oxidative degradation.

Abstract: Anti-inflammatory naphthyl compounds, their preparation and pharmaceutical compositions containing the same. The anti-inflammatory activity has a wide spectrum coupled with low side effects such as gastrointestinal irritancy or oestrongenicity. The compounds possess a chiral center at C-2 and can exist as mixtures of optical isomers or as substantially pure optical isomers.

Abstract: This invention describes novel antioxidant compounds which are esters of .omega.,.omega.-bis(dialkylhydroxyphenyl) alkanols having the formula: ##STR1## wherein R.sub.1 is a tertiary alkyl group having 4-8 carbon atoms;R.sub.2 is alkyl having 1-4 carbon atoms;R.sub.3 is a straight chain or branched alkylene group having 1-4 carbon atoms;x is 1-4,n is 1 or 2, and,Y is a group of the formulas ##STR2## when n is 1, where R.sub.4 is alkyl having from 12 to 24 carbon atoms, phenyl, or phenyl substituted with hydroxy of alkyl having 1 to 4 carbon atoms, or combinations thereof, or ##STR3## when n is 2, where R.sub.5 is a direct bond, a straight chain or branched alkylene having 1 to 8 carbon atoms, or a phenylene group, and m is 0 to 4.

Abstract: Compounds of the formula ##STR1## wherein R.sup.1 is an acyl group or certain optionally halo-substituted hydrocarbyl groups, and X is --CH.sub.2 CH(OCH.sub.3).sub.2, --CH.sub.2 CHO, --CH.dbd.CHOR.sup.2 in which R.sup.2 is acyl, --CHO, --C(O)Cl, --C(O)Br or --C(O)OR in which R is H, a salt-forming cation, an alkyl group or the residue of a pyrethroid alcohol are new pesticides or intermediates therefore. The compounds are prepared using a multi-step synthesis starting from the natural terpene, 3-carene.

Abstract: Prostan-1-ol esters and intermediates for their preparation are described; the former compounds exhibit improved organ specificity and a longer duration of activity at lower dosages than the corresponding non-esterified prostaglandins and are useful, inter alia, in triggering abortion, inducing labor and regulating the menstrual cycle.

Abstract: 4-(6-Substituted naphthyl)butan-2-ols,-butan-2-ones,-pentan-2-ols and -pentan-2-ones bearing a fluoro group in the naphthyl ring, and pro-drugs thereof, are anti-inflammatory agents. A typical embodiment is 4-(4-fluoro-6-methoxy-2-naphthyl)-butan-2-one.

Abstract: Compounds, which have antispasmodic effects, represented by the following formula (I) ##STR1## wherein R.sup.1 and R.sup.2, which may be the same or different, each represents a hydrogen atom, an alkoxy group or, when taken together, R.sup.1 and R.sup.2 represent an alkylenedioxy group; R.sup.3 represents a hydrogen atom, an alkyl group or a cycloalkyl group; R.sup.4, R.sup.5 and R.sup.6, which may be the same or different, each represents a hydrogen atom, an alkoxy group, an alkyl group, a halogen atom, a hydroxyl group or, when two of R.sup.4, R.sup.5 and R.sup.6 are taken together, they represent an alkylenedioxy group; and A represents a straight or branched chain alkylene group having 2 to 10 carbon atoms or an alkylene group having 2 to 10 carbon atoms and interrupted with an oxygen atom forming an ether bond therein, and the therapeutically useful acid-addition salts thereof; and a process for producing the same.

Abstract: A process for the preparation of 1,5-dimethylbicyclo[3,2,1]octan-8-ol is described wherein 1,5-dimethyl-1,5-cyclooctadiene is reacted with a carboxylic acid in the optional presence of acid catalyst to form the corresponding ester of 1,5-dimethylbicyclo[3,2,1]-octan-8-ol which is subsequently hydrolyzed or alcoholyzed to the alcohol product.

Abstract: This disclosure describes novel 15-deoxy-16 hydroxy-16-substituted prostanoic acid analogs in which the C-1 carboxyl is replaced by a primary alcohol and carboxylic acid esters, carbonates and carbomates thereof. The prostanoic carbinols and carboxylic acid esters thereof described herein have utility as bronchodilators as hypotensive agents, and as agents for the control of excessive gastric secretion.

Abstract: Novel polynuclear hindered phenols having three hindered phenol groups each bonded through a methylene group to a substituted aromatic nucleus and methods of making same are provided which have stabilizing activity in organic substances normally susceptible to oxidative degradation.

Abstract: Compounds which contain azo or peroxide linkages as well as the radical of an ultraviolet light stabilizing group are described. These compounds function as polymerization initiators which cause an ultraviolet light stabilization group to be chemically bound to the polymer.

Abstract: Aryl esters of 3,5-di-t-butyl-4-hydroxybenzoic acid are produced by reacting 3,5-di-t-butyl-4-hydroxybenzoic acid with a hydroxyphenol in the presence of di-n-butylether as a non-reactive, organic solvent.

Abstract: Prostan-1-ol esters and intermediates for their preparation are described; the former compounds exhibit improved organ specificity and a longer duration of activity at lower dosages than the corresponding non-esterified prostaglandins and are useful, inter alia, in triggering abortion, inducing labor and regulating the menstrual cycle.

Abstract: Compounds of the formula ##STR1## wherein Y and Z are different and one is nitro or cyano and the other is --N(R).sub.2 wherein R is alkyl or alkylene, preferably of 1 to 4 carbon atoms, and X can be hydrogen, methyl, fluoro or chloro, are dyes having liquid crystal properties.

Abstract: Pharmaceutically active compounds of the formula ##STR1## wherein --OR.sub.1, --OR.sub.2, --OR.sub.3 and --OR.sub.4, which may be the same or different, each represents a free or esterified hydroxyl group and --COOR.sub.5 represents a free or esterified carboxyl group, are provided together with processes for their production and pharmaceutical compositions containing them. Compounds of formula II and III possess valuable cicatrizing and anti-inflammatory properties.

Abstract: Novel 4,5-seco-steroids having anti-inflammatory activity are disclosed herein.